The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease ; volume:9 ; number:1 ; day:15 ; month:9 ; year:2023 ; pages:1-14 ; date:12.2023
Cell death discovery ; 9, Heft 1 (15.9.2023), 1-14, 12.2023
- Urheber
-
Wang, Qiao
Wang, Huizhi
Meng, Wenjia
Liu, Chong
Li, Renpeng
Zhang, Moxuan
Liang, Kun
Gao, Yuan
Du, Tingting
Zhang, Jianguo
Han, Chunlei
Shi, Lin
Meng, Fangang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41420-023-01644-2
- URN
-
urn:nbn:de:101:1-2024020808595969412714
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Qiao
- Wang, Huizhi
- Meng, Wenjia
- Liu, Chong
- Li, Renpeng
- Zhang, Moxuan
- Liang, Kun
- Gao, Yuan
- Du, Tingting
- Zhang, Jianguo
- Han, Chunlei
- Shi, Lin
- Meng, Fangang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
Translational medicine as a new clinical tool and application which improves metabolic diseases: perspectives from 2012 Sino-American symposium on clinical and translational medicine
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
Translational medicine as a new clinical tool and application which improves metabolic diseases: perspectives from 2012 Sino-American symposium on clinical and translational medicine
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis